reticuloendothelial disease. It is not a desirable definition for the chronic leukaemias who are usually re-treated before such a state occurs. So for the chronic leukaemias I propose to regard a remission as ending when the clinical evidence shows clearly that the patient is deteriorating. The indices of this include a significant fall in haemoglobin and rise in the primitive cells of the peripheral blood even although neither symptom has deteriorated to pretreatment levels. * Paper given July 11th, 1958, at 7th International Cancer Congress, Festival Hall, London. It is possible to state at any stage in the observation of a treated patient that a symptom is improving or is stationary or is progressing, relative to the same symptom before treatment. Such a statement can be given a numerical figure. The average of these figures for all the symptoms constitutes a " clinical index " which sums up the condition of the patient and hence measures the quality of remission. An index which falls to a certain limit can then be used to define the end of a remission. Table I shows a number of symptoms so assessed in a case of chronic myeloid leukaemia at 4 months and 12 months after treatment. Opposite each symptom is a number. The code is " 2 " for improvement, " 1 " for an unchanged symptom, and " 0 " for an advancing symptom. A dash means either that a symptom was not present or alternatively that the clinician forgot to annotate it. The average of these figures at 4 months was 2-0. With this mean value the patient was vastly improved. At 12 months, however, the average was 1 -and the remission was ending. Table II shows a similar study of a case of Hodgkin's disease. The mean index at 2 months was 1-8; the patient was much improved. At 4 months, however, the figure was below 1-0 and the remission was over.
The criteria on which the figures are chosen are important but they are too detailed to describe here. Other criteria might well be used. The only measure of validity is that the index arrived at should agree with a clinical impression of the patient as a whole.
The method is not intended to indicate when treatment should be re-instituted -this depends on many other factors. It is only a simple way of expressing the total clinical impression for assessment purposes, in a way which will sort out a welter of symptoms and so facilitate a tabulation of comparative figures on an objective basis. It will not only give us a figure for the length of a remission, it will also estimate the amount of benefit received, and, on a closer analysis, it can be used to look at individual symptoms which might be specifically benefited by a particular agent.
The use of the method is best illustrated by examples in which comparisons have been made between different treatments. The first concerns the approach to measuring response in chronic myeloid leukaemia. Chronic Myeloid Leukaemia Fig. 1-5 each summarise the career of a case of chronic myeloid leukaemia treated by various agents. The sequence of events will be familiar to all clinicians but perhaps less so to those working in the experimental field. These histories are being used to illustrate what I think to be a general truth, that only the first treatment of a leukaemic patient should be used in the comparative assessment of compounds.
The height of the column denotes the period during which the patient was in remission. If no remission occurred during a treatment, that is to say, if the index was 1-0 or less, the column has been barred diagonally. The patient illustrated in Fig. 1 was given 32P as the first treatment with in consequence a remission of over 2 years. At the end of this remission he was given the chemical compound B.E.P. (1: 3-bis (ethyleneiminosulphonylpropane)), and a further good remission of 11 months followed. This ended when the patient stopped taking B.E.P. on account of nausea. Myleran was, therefore, substituted.
The response was slower and the remission was shorter. The last three courses with mercaptopurine, myleran and a last treatment with 32P were all ineffective.
This case illustrates that the duration of remissions steadily diminished and that the same 32P which apparently was most suitable at an early stage, was entirely unhelpful terminally.
This next case ( Fig. 2) , was given splenic irradiation as the first method of treatment. This patient had a prolonged remission for over three and a half years. The treatment was changed to myleran because the spleen seemed to be becoming resistant. This remission lasted for about one year. The patient then deteriorated rapidly.
On the basis of these cases it might seem that myleran was rather ineffectual compared with irradiation methods. Fig. 3 however shows myleran in a very different light. This patient was treated by myleran as the first and only treatment. She was kept in good health for three and a half years and died a few months after the remission ended. It is interesting to note here that at the beginning the amount of myleran required to give freedom from symptoms was small; later, sustained maintenance dosage was required. The last patient, (Fig. 5) , was treated by monthly doses of triethylene melamine (T.E.M.) and did well for 16 months. At the end of the remission B.E.P. was given unsuccessfully. X-ray therapy to the spleen was effective for a very short time; no benefit was obtained with myleran.
These are examples; similar pictures could be shown of other chemotherapeutic agents. These diagrams all illustrate the principle of diminishing returns. They serve to show how important it is to test compounds in patients at a stage when they are capable of responding and it would seem important to evaluate a new compound on its use as the first agent in treatment.
If this is accepted it follows that very few centres to-day can get an answer about a new treatment quickly, based on the first treatment of their own clinical material. Of recent years the difficulty has further increased because many patients have already been treated by individual physicians before reaching a centre engaged in clinical investigation.
The conclusion is obvious that important comparisons should be done on a national or international basis. This would imply rules for random selection of patients and carefully thought out standards of measurement. For future assessments of chemotherapeutic compounds in chronic myeloid leukaemia it is suggested that splenic irradiation might well be the best control treatment; this does not mean resurrecting the dusty histories of 20 years ago to compare with a new compound, but rather the selection of contemporary cases for treatment, on a random basis.
Another point is illustrated by these five patients. T.E.M.-later treatment .
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It would seem that for both first and later treatments nitrogen mustard appeared to be a fraction superior to T.E.M. but the difference if present was very small. The figures also suggest that the quality of a remission was about the same for first and for later treatments with either compound.
(d) Side effects
An important consideration in the comparison of two compounds relates to the undesirable side effects. Nitrogen mustard has the well known disadvantage of inducing transient gastrointestinal symptoms and sometimes venous thrombosis; T.E.M. is given orally in enteric coated tablets and if given in instalments is free of these side effects. This point is conceded and needs no elaboration.
The depression of the haemopoietic system can perhaps be briefly contrasted by examining the effects on two elements of the circulating blood-the haemoglobin and the platelets. The comparative effects of the two compounds on haemoglobin is shown in Table VI which is based on all patients whether they benefited or not provided that the data on their blood counts was available, and irrespective of the order in which compounds were given. Depression of haemoglobin has been taken as a fall of 10 per cent or more following treatment. Eighteen per cent of the HN2 patients showed this against 23 per cent of the T.E.M. patients. If this difference were significant it would be important to the clinician. It is, however, not significant, and for both compounds the recovery time of the haemoglobin was the same. There was no difference in the haemoglobin depression between first and later treatments with either compound. The standard measurement of platelet depression was a reduction of 25 per cent or more in the platelet count. The figures of 33 per cent for HN2 and 35 per cent for T.E.M. are very close, and the recovery times were similar for the two compounds. There was no difference between first and later treatments with either compound.
Studies of the other cells of the circulating blood have not shown differences between HN2 and T.E.M.
For the future evaluation of new compounds for generalised Hodgkin's disease a control method of treatment is required. Nitrogen mustard itself would be suitable, on the grounds of the vast clinical experience which has been accumulated. These clinical comparisons do not have the elegance of laboratory experiment. For example nitrogen mustard and T.E.M. have been compared on animal tumours, notably by Druckrey et al. (1956) and by Oettel and Wilhelm (1957 The differences shown in Tables VIII and IX are not significant and they do not support the hypothesis that the combined treatment carried any advantage.
A similar examination based on other types of malignant disease or with other compounds might not lead to the same conclusion. This study applies only to Hodgkin's disease and it is included to show that the method of measurement must vary with the information one is looking for.
SUMMARY
(1) The present-day needs for the advancement of chemotherapy include critical comparisons using defined clinical indices.
(2) The most valuable comparisons are between the effects of different agents as the first treatment and using the average length of remission as the standard. This requires collaborative work between centres in order to get information that is speedy and significant.
(3) Other effects such as the remission rate or the quality of a remission can equally be assessed by the use of a clinical index, and for certain purposes the survival time may be useful.
(4) For each disease studied a well tested method of treatment is required as a control for a new compound. This implies that treatments should be carried out on a random basis.
